AGT‑115 is a re-engineered form of human erythropoietin (EPO) that ArmaGen has engineered for the treatment of Parkinson’s disease (PD) and stroke.1 EPO is a potent neuroprotective agent, however; it cannot cross the BBB in natural form. AGT-115, a neurotrophin fusion molecule, overcomes this obstacle by crossing the BBB via receptor-mediated transport.1

In preclinical studies, AGT-m115 reduced stroke volume and neural deficit by 98% in a mouse model of stroke.2 Additionally, AGT-m115 was neuroprotective in a mouse model of Parkinson’s disease.3


References:

1 Boado RJ, Hui EK, Lu JZ, Pardridge WM (2010) Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther. 333:961-9

2 Fu A, Hui EK, Lu JZ, Boado RJ, Pardridge WM (2011) Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein. Brain Res. 1369:203-7

3 Zhou QH, Hui EK, Lu JZ, Boado RJ, Pardridge WM (2011) Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson’s disease in the mouse. Brain Res. 1382:315-20